Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

April 4, 2019

TG Therapeutics’ Umbralisib Proves Safe, Effective for Previously Treated Marginal Zone Lymphoma

News

TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half of ... Read more

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell ... Read more

February 25, 2019

Exposure to Glyphosate in Herbicides Increases Risk of Non-Hodgkin’s Lymphoma, Study Says

News

Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based Herbicides ... Read more

October 26, 2018

Orgenesis, Hemogenyx Collaborating on Cell Replacement Technology for Blood Cancers

News

Orgenesis has partnered with Hemogenyx Pharmaceuticals to drive the development and commercialization of Hemogenyx’s human postnatal hemogenic endothelial cell (Hu-PHEC) technology for the treatment of blood cancers. Hu-PHEC is a cell replacement technology designed ... Read more

October 24, 2018

Leukemia and Lymphoma Society Grants $5M for Development of Blood Cancer Immunotherapies

News

A team of Texas researchers received a grant of $5 million from the Leukemia and Lymphoma Society to develop targeted immunotherapies for blood cancers. The Specialized Center of Research (SCOR) grant will provide ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

September 10, 2018

Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows

News

TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. The ... Read more